| 词条 | Enavatuzumab |
| 释义 |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 457124199 | type = mab | image = | alt = | mab_type = mab | source = zu/o | target = TWEAK receptor | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number_Ref = {{cascite|changed|CAS}} | CAS_number = 1062149-33-0 | UNII_Ref = {{fdacite|changed|FDA}} | UNII = 914910XFBB | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | C=6334 | H=9792 | N=1700 | O=2000 | S=42 | molecular_weight = 143.1 kg/mol | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | KEGG = D09896 }} Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors. Enavatuzumab was developed by Facet Biotech Corp.[1] References1. ^{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/enavatuzumab.pdf}} {{Monoclonals for tumors}}{{Cytokine receptor modulators}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}} 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。